Today, Fool.com health-care analysts Brenton Flynn and David Williamson look at an unexpected downgrade of Amarin from Wedbush Securities. While Wedbush still believes the company makes for an attractive target, it's less optimistic that a Big Pharma buyout will happen as early as previously expected.
When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.